{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Timolol+0.5%25+Ophthalmic+Solution",
    "query": {
      "intervention": "Timolol 0.5% Ophthalmic Solution"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 60,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Timolol+0.5%25+Ophthalmic+Solution&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T16:31:25.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04830397",
      "title": "Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "QLS-101",
          "type": "DRUG"
        },
        {
          "name": "Timolol Maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qlaris Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2021-03-31",
      "completion_date": "2022-02-17",
      "has_results": false,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Albany, Georgia",
      "locations": [
        {
          "city": "Albany",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04830397"
    },
    {
      "nct_id": "NCT00465803",
      "title": "A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travoprost 0.004%/timolol 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Travoprost ophthalmic solution, 0.004%",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate ophthalmic solution, 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2007-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465803"
    },
    {
      "nct_id": "NCT07495852",
      "title": "Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Gen 2 Travoprost Intracameral Implant",
          "type": "DRUG"
        },
        {
          "name": "Timolol eye drops 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "placebo eye drops",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2026-02-17",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Dothan, Alabama",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07495852"
    },
    {
      "nct_id": "NCT01257698",
      "title": "Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Macular Hole",
        "Retinal Detachment"
      ],
      "interventions": [
        {
          "name": "Dorzolamide 2%-timolol 0.5% topical eyedrops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mid Atlantic Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 21,
      "start_date": "2010-02",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-09-04",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257698"
    },
    {
      "nct_id": "NCT06883123",
      "title": "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Simbrinza 0.2%-1% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rocklatan 0.02%-0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Cosopt PF 2%-0.5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prairie Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-14",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883123"
    },
    {
      "nct_id": "NCT02207491",
      "title": "Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 411,
      "start_date": "2014-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-13",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207491"
    },
    {
      "nct_id": "NCT07384767",
      "title": "Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mohs Micrographic Surgery",
        "Excision Margin"
      ],
      "interventions": [
        {
          "name": "Timolol 0.5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Hydrogel of placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2026-10-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 2,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07384767"
    },
    {
      "nct_id": "NCT04742283",
      "title": "Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "DE-126 Ophthalmic Solution 0.002% QD",
          "type": "DRUG"
        },
        {
          "name": "Timolol Maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2020-12-17",
      "completion_date": "2021-12-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 41,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04742283"
    },
    {
      "nct_id": "NCT02250612",
      "title": "SYL040012, Treatment for Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "1 drop of 0.375% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.750% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.125% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.5% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.5 % timolol maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sylentis, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2014-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 4,
      "location_summary": "Artesia, California • Petaluma, California • Morrow, Georgia + 1 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250612"
    },
    {
      "nct_id": "NCT01533376",
      "title": "Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sturge Weber Syndrome",
        "Port-wine Mark"
      ],
      "interventions": [
        {
          "name": "Timolol",
          "type": "DRUG"
        },
        {
          "name": "Preservative free artificial tear gel.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "2 Years to 10 Years"
      },
      "enrollment_count": 3,
      "start_date": "2012-02",
      "completion_date": "2019-02",
      "has_results": false,
      "last_update_posted_date": "2019-03-21",
      "last_synced_at": "2026-09-25T16:31:25.366Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01533376"
    }
  ]
}